Lars Lindholm

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

Hypertension, Cardiovascular Disease, Endpoint Reduction +7

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

Lennart Hansson, Lars Lindholm, Leo Niskanen et al. · The Lancet · 1999 · 2K citations

Hypertension, Cardiovascular Disease, Antihypertensive Agents +10

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Björn Dahlöf, L. Hansson, Lars Lindholm et al. · The Lancet · 1991 · 1.9K citations

Hypertension, Cardiovascular Epidemiology, Cardiovascular Disease +10

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lars Lindholm, Hans Ibsen, Björn Dahlöf et al. · The Lancet · 2002 · 1.6K citations

Hypertension, Cardiovascular Disease, Health Policy +9

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

Lennart Hansson, Lars Lindholm, Tord Ekbom et al. · The Lancet · 1999 · 1.4K citations

Hypertension, Aging, Health Policy +13